HUDSON TECHNOLOGIES INC /NY - Quarter Report: 2008 July (Form 10-Q)
UNITED STATES
Securities and Exchange Commission
Washington, D.C. 20549
Form 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2008
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934
For the transition period from ____________ to ____________
Commission file number 1-13412
_____________________
Hudson Technologies, Inc.
_____________________
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
13-3641539 (I.R.S. Employer Identification No.) |
|
|
|
|
P.O. Box 1541 |
|
|
One Blue Hill Plaza Pearl River, New York (Address of principal executive offices) |
10965 (Zip Code) |
|
|
|
|
Registrant's telephone number, including area code |
(845) 735-6000 |
|
|
|
(Former name, former address, and former fiscal year, if changed since last report)
_____________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes [X] No [ ]Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", and "smaller reporting company" in Rule 12b-2 of the Exchange Act:
Large accelerated filer |
[ ] |
Accelerated filer |
[ ] |
Non-accelerated filer (do not check if a smaller reporting company) |
[ ] |
Smaller reporting company |
[X] |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes [ ] No [X]State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date:
Common stock, $0.01 par value |
19,406,548 shares |
Class |
Outstanding at July 31, 2008 |
Hudson Technologies, Inc.
Index
Part |
Item |
Page |
|
Part I. |
Financial Information |
||
Item 1 |
- Financial Statements |
||
- Consolidated Balance Sheets |
3 |
||
- Consolidated Statements of Operations |
4 |
||
- Consolidated Statements of Cash Flows |
5 |
||
- Notes to the Consolidated Financial Statements |
6 |
||
Item 2 |
- Management's Discussion and Analysis of Financial Condition and Results of Operations |
11 |
|
Item 3 |
- Quantitative and Qualitative Disclosures About Market Risk |
16 |
|
Item 4T |
- Controls and Procedures |
16 |
|
Part II. |
Other Information |
||
Item 1 |
- Legal Proceedings |
18 |
|
Item 2 |
- Unregistered Sales of Equity Securities and Use of Proceeds |
18 |
|
Item 6 |
- Exhibits |
18 |
|
Signatures |
19 |
Page 2
Part I - FINANCIAL INFORMATION
Hudson Technologies, Inc. and subsidiaries
Consolidated Balance Sheets
(Amounts in thousands, except for share and par value amounts)
|
June 30, 2008 |
December 31, 2007 |
|||
|
(unaudited) |
|
|||
Assets |
|
|
|||
Current assets: |
|
|
|||
|
Cash and cash equivalents |
$ 824 |
$ 283 |
||
|
Trade accounts receivable - net of allowance for doubtful |
|
|
||
|
accounts of $328 and $276 |
7,435 |
1,746 |
||
|
Inventories |
15,217 |
12,602 |
||
|
Prepaid expenses and other current assets |
400 |
242 |
||
|
Total current assets |
23,876 |
14,873 |
||
|
|
|
|||
Property, plant and equipment, less accumulated depreciation and amortization |
3,088 |
2,881 |
|||
Other assets |
118 |
46 |
|||
Deferred tax assets |
1,520 |
1,520 |
|||
Intangible assets, less accumulated amortization |
57 |
66 |
|||
|
Total Assets |
$28,659 |
$19,386 |
||
|
======== |
======== |
|||
|
|
|
|||
Liabilities and Stockholders' Equity |
|
|
|||
Current liabilities: |
|
|
|||
|
Accounts payable and accrued expenses |
$ 3,434 |
$ 3,568 |
||
|
Accrued payroll |
742 |
638 |
||
|
Short-term debt and current maturities of long-term debt |
7,546 |
3,124 |
||
|
Total current liabilities |
11,722 |
7,330 |
||
Long-term debt, less current maturities |
6,217 |
6,493 |
|||
|
Total Liabilities |
17,939 |
13,823 |
||
|
|
|
|||
Commitments and contingencies |
|
|
|||
|
|
|
|||
Stockholders' equity: |
|
|
|||
|
Preferred stock shares authorized 5,000,000 |
|
|
||
|
Series A Convertible Preferred stock, $.01 par value ($100 |
|
|
||
|
liquidation preference value); shares authorized 150,000 |
-- |
-- |
||
|
Common stock, $0.01 par value; shares authorized 50,000,000 |
|
|
||
|
issued and outstanding 19,406,548 and 19,072,264 |
194 |
191 |
||
|
Additional paid-in capital |
35,753 |
35,349 |
||
|
Accumulated deficit |
(25,227) |
(29,977) |
||
|
Total Stockholders' Equity |
10,720 |
5,563 |
||
|
|
|
|||
Total Liabilities and Stockholders' Equity |
$28,659 |
$19,386 |
|||
|
======= |
======= |
See accompanying Notes to the Consolidated Financial Statements.
Page 3
Hudson Technologies, Inc. and subsidiaries
Consolidated Statements of Operations
(unaudited)
(Amounts in thousands, except for share and per share amounts)
|
Three month period ended June 30, |
Six month period ended June 30, |
|||||||
2008 |
2007 |
2008 |
2007 |
||||||
|
|
|
|
|
|||||
Revenues |
$13,089 |
$11,307 |
$24,455 |
$19,424 |
|||||
Cost of sales |
7,945 |
8,358 |
15,715 |
14,917 |
|||||
Gross Profit |
5,144 |
2,949 |
8,740 |
4,507 |
|||||
|
|
|
|
|
|||||
Operating expenses: |
|
|
|
|
|||||
|
Selling and marketing |
568 |
480 |
1,119 |
888 |
||||
|
General and administrative |
771 |
836 |
1,760 |
1,573 |
||||
|
Compensation expense for stock purchases |
-- |
4,338 |
-- |
4,338 |
||||
|
Total operating expenses |
1,339 |
5,654 |
2,879 |
6,799 |
||||
|
|
|
|
|
|
||||
|
|
|
|
|
|||||
Operating income (loss) |
3,805 |
(2,705) |
5,861 |
(2,292) |
|||||
|
|
|
|
|
|||||
Other income (expense): |
|
|
|
|
|||||
|
Interest expense |
(315) |
(167) |
(569) |
(306) |
||||
|
Interest income |
1 |
3 |
2 |
12 |
||||
|
Total other income (expense) |
(314) |
(164) |
(567) |
(294) |
||||
|
|
|
|
|
|||||
Income (loss) before income taxes |
3,491 |
(2,869) |
5,294 |
(2,586) |
|||||
|
|
|
|
|
|||||
Income tax provision (benefit) |
492 |
(1,254) |
544 |
(1,254) |
|||||
|
|
|
|
|
|||||
Net income (loss) |
$2,999 |
($1,615) |
$4,750 |
($1,332) |
|||||
|
====== |
====== |
====== |
====== |
|||||
|
|
|
|
|
|
||||
Net income (loss) per common share - Basic |
$0.16 |
($0.06) |
$0.25 |
($0.05) |
|||||
|
===== |
====== |
===== |
===== |
|||||
Net income (loss) per common share - Diluted |
$0.15 |
($0.06) |
$0.23 |
($0.05) |
|||||
|
===== |
====== |
===== |
===== |
|||||
Weighted average number of shares |
|
|
|
|
|||||
|
outstanding - Basic |
19,339,551 |
25,905,060 |
19,184,409 |
    25,910,233 |
||||
|
======== |
======== |
======== |
======== |
|||||
Weighted average number of shares |
|
|
|
|
|||||
|
outstanding - Diluted |
20,464,163 |
25,905,060 |
20,259,665 |
25,910,233 |
||||
|
======== |
======== |
======== |
======== |
|||||
|
|
|
|
|
See accompanying Notes to the Consolidated Financial Statements
Page 4
Hudson Technologies, Inc. and subsidiaries
Consolidated Statements of Cash Flows
Increase (Decrease) in Cash and Cash Equivalents
(unaudited)
(Amounts in thousands)
Six month period |
||
ended June 30, |
||
2008 |
2007 |
|
Cash flows from operating activities: |
||
Net income (loss) |
$4,750 |
($1,332) |
Adjustments to reconcile net income (loss) |
||
to cash provided (used) by operating activities: |
||
Depreciation and amortization |
268 |
284 |
Allowance for doubtful accounts |
60 |
45 |
Issuance of stock options for services |
12 |
54 |
Compensation expense for stock purchases |
-- |
4,338 |
Deferred tax benefit |
-- |
(1,268) |
Changes in assets and liabilities: |
||
Trade accounts receivable |
(5,749) |
(4,188) |
Inventories |
(2,615) |
5,644 |
Prepaid expenses and other current assets |
(158) |
(128) |
Other assets |
(72) |
(4) |
Accounts payable and accrued expenses |
(30) |
(2,107) |
Cash provided (used) by operating activities |
(3,534) |
1,338 |
Cash flows from investing activities: |
||
Additions to patents |
(4) |
(6) |
Additions to property, plant, and equipment |
(462) |
(260) |
Cash used by investing activities |
(466) |
(266) |
Cash flows from financing activities: |
||
Purchase of common stock - net |
-- |
(3,954) |
Issuance of common stock - net |
395 |
-- |
Proceeds from short-term debt - net |
4,411 |
(2,898) |
Repayment of long-term debt |
(565) |
(349) |
Proceeds of long-term debt |
300 |
7,000 |
Cash provided (used) by financing activities |
4,541 |
(201) |
Increase in cash and cash equivalents |
541 |
871 |
Cash and cash equivalents at beginning of period |
283 |
593 |
Cash and cash equivalents at end of period |
$824 |
$1,464 |
====== |
====== |
|
__________________________________________________________________ |
||
Supplemental disclosure of cash flow information: |
||
Cash paid during period for interest |
$637 |
$306 |
Cash paid for income taxes |
$194 |
$15 |
Supplemental disclosure of non-cash investing and financing activities |
||
Deferred financing costs |
$68 |
$ -- |
See accompanying Notes to the Consolidated Financial Statements.
Page 5
Hudson Technologies, Inc. and subsidiaries
Notes to the Consolidated Financial Statements
Note 1 - Summary of significant accounting policies
Business
Hudson Technologies, Inc., ("Hudson" or the "Company") incorporated under the laws of New York on January 11, 1991, is a refrigerant services company providing innovative solutions to recurring problems within the refrigeration industry. The Company's products and services are primarily used in commercial air conditioning, industrial processing and refrigeration systems, including (i) refrigerant sales, (ii) refrigerant management services consisting primarily of reclamation of refrigerants and (iii) RefrigerantSide® Services performed at a customer's site, consisting of system decontamination to remove moisture, oils and other contaminants. In addition, RefrigerantSide® Services includes predictive and diagnostic services for industrial and commercial refrigeration applications, which are designed to predict potential catastrophic problems and identify inefficiencies in an operating system. The Company's Chill Smart™, Chiller Chemistry™, Fluid Chemistry ™, and Performance Optimization are predictive and diagnostic service offerings. The Company operates through its wholly-owned subsidiary, Hudson Technologies Company.
The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and with the instructions of Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. The financial information included in the quarterly report should be read in conjunction with the Company's audited financial statements and related notes thereto for the year ended December 31, 2007. Operating results for the six month period ended June 30, 2008 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2008.
In the opinion of management, all estimates and adjustments considered necessary for a fair presentation have been included and all such adjustments were normal and recurring.
Consolidation
The consolidated financial statements represent all companies of which Hudson directly or indirectly has majority ownership or otherwise controls. Significant intercompany accounts and transactions have been eliminated. The Company's consolidated financial statements include the accounts of wholly-owned subsidiaries Hudson Holdings, Inc. and Hudson Technologies Company.
Fair value of financial instruments
The carrying values of financial instruments including trade accounts receivable and accounts payable approximate fair value at June 30, 2008, because of the relatively short maturity of these instruments. The carrying value of short-and long-term debt approximates fair value, based upon quoted market rates of similar debt issues, as of December 31, 2007 and June 30, 2008.
Credit risk
Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of temporary cash investments and trade accounts receivable. The Company maintains its temporary cash investments in highly-rated financial institutions and, at times, the balances exceed FDIC insurance coverage. The Company's trade accounts receivables are primarily due from companies throughout the United States. The Company reviews each customer's credit history before extending credit.
The Company establishes an allowance for doubtful accounts based on factors associated with the credit risk of specific accounts, historical trends, and other information. The carrying value of the Company's accounts receivable is reduced by the established allowance for doubtful accounts. The allowance for doubtful accounts includes any accounts receivable balances that are determined to be uncollectible, along with a general reserve for the remaining accounts receivable balances. The Company adjusts its general or specific reserves based on factors that affect the collectability of the accounts receivable balances.
For the six month period ended June 30, 2008, one customer accounted for approximately 11% of the Company's revenues. For the six month period ended June 30, 2007, one customer accounted for approximately 16% of the Company's revenues.
The loss of a principal customer or a decline in the economic prospects of and/or a reduction in purchases of the Company's products or services by any such customer could have an adverse effect on the Company's future financial position and results of operations.
Page 6
Cash and cash equivalents
Temporary investments with original maturities of ninety days or less are included in cash and cash equivalents.
Inventories
Inventories, consisting primarily of refrigerant products available for sale, are stated at the lower of cost, on a first-in first-out basis, or market.
Property, plant, and equipment
Property, plant, and equipment are stated at cost, including internally manufactured equipment. The cost to complete equipment that is under construction is not considered to be material to the Company's financial position. Provision for depreciation is recorded (for financial reporting purposes) using the straight-line method over the useful lives of the respective assets. Leasehold improvements are amortized on a straight-line basis over the shorter of economic life or terms of the respective leases. Costs of maintenance and repairs are charged to expense when incurred.
Due to the specialized nature of the Company's business, it is possible that the Company's estimates of equipment useful life periods may change in the future.
Revenues and cost of sales
Revenues are recorded upon completion of service or product shipment and passage of title to customers in accordance with contractual terms. The Company evaluates each sale to ensure collectability. In addition, each sale is based on an arrangement with the customer and the sales price to the buyer is fixed. License fees are recognized over the period of the license based on the respective performance measurements associated with the license. Royalty revenues are recognized when earned. Cost of sales is recorded based on the cost of products shipped or services performed and related direct operating costs of the Company's facilities. To the extent that the Company charges its customers shipping fees such amounts are included as a component of revenue and the corresponding costs are included as a component of cost of sales.
The Company's revenues are derived from refrigerant and reclamation sales and RefrigerantSide® Services, including license and royalty revenues. The revenues for each of these lines are as follows:
Six Month Period Ended June 30, |
2008 |
2007 |
(in thousands, unaudited) |
|
|
Refrigerant and reclamation sales |
$22,529 |
$17,595 |
RefrigerantSide® Services |
1 ,926 |
1,829 |
Total |
$24,455 |
$19,424 |
|
===== |
====== |
Income taxes
The Company utilizes the asset and liability method for recording deferred income taxes, which provides for the establishment of deferred tax asset or liability accounts based on the difference between tax and financial reporting bases of certain assets and liabilities. The tax benefit associated with the Company's net operating loss carry forwards ("NOL's") is recognized to the extent that the Company is expected to recognize future taxable income. The Company has assessed the recoverability of its deferred tax assets based on its expectation that it will recognize future taxable income and accordingly has adjusted its valuation allowance for this asset. As of June 30, 2008, the total deferred tax asset is $1,520,000. Certain states either do not allow or limit NOL's and as such the Company will be liable for certain state taxes. To the extent that the Company utilizes its NOL's, it will not pay tax on such amount but will be subject to the federal alternative minimum tax. In addition, to the extent that the Company's net income, if any, exceeds the annual NOL limitation it will pay income taxes based on the existing statutory rates. As a result of an Internal Revenue Service audit, the 2006 and prior tax years have been closed. The Company operates in many states throughout the United States and, as of June 30, 2008, the various states statue of limitations remain open for tax years subsequent to 2003.
On June 28, 2007, Fleming U.S. Discovery Fund III, L.P. and Fleming U.S. Offshore Discovery Fund III, L.P. (individually and collectively "Fleming Funds") sold a total of approximately 14,900,000 shares of Hudson's common stock in a series of transactions involving the Company and certain members of the Company's management (the "Transactions"). Prior to the Transactions, the Fleming Funds owned in the aggregate approximately 19,100,000 shares, or 74% of the Company's outstanding common stock. Under Section 382 of the Internal Revenue Code of 1986, ("Code") as amended, the sale by Fleming Funds of their shares resulted in a "change in control", which limits the Company's ability to utilize its existing NOL's to approximately $1,300,000 annually.
Page 7
Income (Loss) per common and equivalent shares
If dilutive, common equivalent shares (common shares assuming exercise of options and warrants) utilizing the treasury stock method are considered in the presentation of dilutive earnings per share. For the three month period ended June 30, 2008 and 2007, the number of common equivalent shares included and excluded in the calculation of dilutive income per common share was 2,839,091 and 219,625 and none and 2,251,700. For the six month period ended June 30, 2008 and 2007, the number of common equivalent shares included and excluded in the calculation of dilutive income per common share was 2,839,091 and 219,625 and none and 2,251,700 and the dilutive effect of the common equivalent shares reduced the basic calculation of income per share from $0.16 to $0.15 for diluted income per share. For the six month period ended June 30, 2007, the effect on net income per share of equivalent shares was not dilutive.
Estimates and risks
The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect reported amounts of certain assets and liabilities, the disclosure of contingent assets and liabilities, and the results of operations during the reporting period. Actual results could differ from these estimates.
The Company participates in an industry that is highly regulated, changes in which could affect operating results. Currently the Company purchases virgin, non chlorofluorocarbon ("CFC") based, and reclaimable, primarily CFC based, refrigerants from suppliers and its customers. Effective January 1, 1996, the Clean Air Act (the "Act") prohibited the production of CFC refrigerants and limited the production of hydrochlorofluorocarbons ("HCFC") refrigerants. Additionally, effective January 2004, the Act further limited the production of HCFC refrigerants and federal regulations were enacted which impose limitations on the importation of certain virgin HCFC refrigerants. Under the Act, production of certain HCFC refrigerants are scheduled to be phased out by the year 2020, and production of all HCFC refrigerants is scheduled to be phased out by 2030. Notwithstanding the limitations under the Act, the Company believes that sufficient quantities of new and used refrigerants will continue to be available to it at a reasonable cost for the foreseeable future. To the extent that the Company is unable to source sufficient quantities of refrigerants or is unable to obtain refrigerants on commercially reasonable terms or experiences a decline in demand for refrigerants, the Company could realize reductions in refrigerant processing and possible loss of revenues, which would have a material adverse affect on operating results.
The Company is subject to various legal proceedings. The Company assesses the merit and potential liability associated with each of these proceedings. In addition, the Company estimates potential liability, if any, related to these matters. To the extent that these estimates are not accurate, or circumstances change in the future, the Company could realize liabilities, which would have a material adverse effect on operating results and its financial position.
Impairment of long-lived assets and long-lived assets to be disposed of
The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less the cost to sell.
Recent accounting pronouncements
In September 2006, the Financial Accounting Standards Board ("FASB") issued FASB statement No. 157 ("SFAS No. 157"), "Fair Value Measurements," which establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. SFAS No. 157 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. SFAS No. 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The FASB agreed to defer the effective date of Statement 157 for one year for non-financial assets and non-financial liabilities that are recognized or disclosed at fair value in the financial statements on a nonrecurring basis. There is no deferral for financial assets and financial liabilities, nor for the rare non-financial assets and non-financial liabilities that are remeasured at fair value at least annually. The adoption of SFAS No. 157 did not have a material impact on the Company's results of operations or its financial position.
Page 8
Note 2 - Share-based compensation
Share-based compensation represents the cost related to share-based awards, typically stock options, granted to employees, non-employees, officers and directors. Share-based compensation is measured at grant date, based on the estimated fair value of the award, and such amount is charged to compensation expense on a straight-line basis (net of estimated forfeitures) over the requisite service period. For the six month period ended June 30, 2008 and 2007, the share-based compensation expense of $12,000 and $54,000, respectively, is reflected in general and administrative expenses in the consolidated statements of operations.
Share-based awards have historically been stock options issued pursuant to the terms of the Company's 1994, 1997 and 2004 stock option plans (the "Plans"), described below. The Board of Directors administers the Plans. As of June 30, 2008, the Plans authorized the issuance of stock options to purchase 2,500,000 shares of the Company's common stock and, as of June 30, 2008 there were 400,000 shares of the Company's common stock available for issuance for future stock option grants.
Stock options are awards, which allow the recipient to purchase shares of the Company's common stock at a fixed price, are typically granted at an exercise price equal to the Company's stock price at the date of grant. Typically, the Company's stock option awards have vested from immediately to two years from the grant date and have had a contractual term ranging from five to ten years.
During the six month period ended June 30, 2008 and 2007, the Company issued stock options of 180,000 and none, respectively, and the fair value of these awards was $96,000 and none, respectively. At June 30, 2008, there was $84,000 of unrecognized compensation cost related to non-vested previously granted option awards.
Effective October 31, 1994, the Company adopted an Employee Stock Option Plan ("1994 Plan") pursuant to which 725,000 shares of common stock were reserved for issuance upon the exercise of options designated as either (i) options intended to constitute incentive stock options ("ISOs") under the Internal Revenue Code of 1986, as amended, ("Code") or (ii) nonqualified options. ISOs could have been granted under the 1994 Plan to employees and officers of the Company. Non-qualified options could have been granted to consultants, directors (whether or not they are employees), employees or officers of the Company. Effective November 1, 2004, the Company's ability to grant options under the 1994 Plan expired.
Effective July 25, 1997, the Company adopted its 1997 Employee Stock Option Plan, which was amended on August 19, 1999, ("1997 Plan") pursuant to which 2,000,000 shares of common stock were reserved for issuance upon the exercise of options designated as either (i) ISOs under the Code, or (ii) nonqualified options. ISOs could have been granted under the 1997 Plan to employees and officers of the Company. Non-qualified options could have been granted to consultants, directors (whether or not they are employees), employees or officers of the Company. Effective September 11, 2007, the Company's ability to grant options under the 1997 Plan expired.
Effective September 10, 2004, the Company adopted its 2004 Stock Incentive Plan ("2004 Plan") pursuant to which 2,500,000 shares of common stock are currently reserved for issuance upon the exercise of options, designated as either (i) ISOs under the Code or (ii) nonqualified options, restricted stock, deferred stock or other stock-based awards. ISOs may be granted under the 2004 Plan to employees and officers of the Company. Non qualified options, restricted stock, deferred stock or other stock-based awards may be granted to consultants, directors (whether or not they are employees), employees or officers of the Company. Stock appreciation rights may also be issued in tandem with stock options. Unless the 2004 Plan is sooner terminated, the ability to grant options or other awards under the 2004 Plan will expire on September 10, 2014.
Options granted under the 2004 Plan may not be granted at a price less than the fair market value of the common stock on the date of grant (or 110% of fair market value in the case of persons holding 10% or more of the voting stock of the Company). Non-qualified options granted under the 2004 Plan may not be granted at a price less than the fair market value of the common stock. Options granted under the 2004 Plan expire not more than ten years from the date of grant (five years in the case of ISOs granted to persons holding 10% or more of the voting stock of the Company).
All stock options have been granted to employees and non-employees at exercise prices equal to or in excess of the market value on the date of the grant.
The Company determines the fair value of shared based awards at the grant date by using the Black-Scholes option-pricing model, and is incorporating the simplified method to compute expected lives of share based awards with the following weighted-average assumptions used for grants since 1995:
Page 9
Six Month Period ended June 30, |
2008 |
|
Assumptions |
|
|
|
Dividend Yield |
0 % |
|
Risk free interest rate |
2.9% |
|
Expected volatility |
55% |
|
Expected lives |
5 years |
A summary of the status of the Company's 1994, 1997 and 2004 Plans as of December 31, 2007 and June 30, 2008 and changes for the periods ending on those dates is presented below:
Stock Option Plan Grants |
Shares |
Weighted Average Exercise Price |
Outstanding at December 31, 2006 |
2,287,143 |
$1.47 |
|
970,000 |
$0.85 |
|
(242,500) |
$3.07 |
|
(5,000) |
$0.85 |
Outstanding at December 31, 2007 |
3,009,643 |
$1.15 |
|
180,000 |
$1.15 |
|
(60,000) |
$1.09 |
|
(300,161) |
$0.96 |
Outstanding at June 30, 2008 |
2,829,482 |
$1.17 |
======= |
The following is the weighted average contractual life in years and the weighted average exercise price as of June 30, 2008 of:
Weighted Average |
|||
Number of |
Remaining |
Weighted Average |
|
|
Options |
Contractual Life |
Exercise Price |
Options outstanding |
2,829,482 |
7.1 years |
$1.17 |
Options vested |
2,666,982 |
7.6 years |
$1.17 |
|
|
|
|
The following is the intrinsic value as of June 30, 2008 of:
Options outstanding |
$3,859,000 |
Options vested |
$ 47,000 |
Options exercised |
$ 484,000 |
|
|
The intrinsic value of options exercised during the year ended December 31, 2007 period was $2,000
The following is the weighted average fair value for the six month period ended June 30, 2008 of:
Options granted |
$1.15 |
Options vested |
$1.28 |
Note 3 - Stock repurchase
On June 28, 2007, the Company purchased and retired approximately 5,700,000 shares of its common stock from the Fleming Funds at a purchase price of $0.65 per share, for total consideration of approximately $3,700,000. Additionally, certain members of the Company's management, in separate private transactions, purchased approximately 9,200,000 shares of the Company's common stock from the Fleming Funds at a purchase price of $0.65 per share, for a total consideration of approximately $6,000,000. The shares purchased by management are unregistered shares and management did not receive registration rights in connection with their purchase of their shares.
On June 29, 2007 the Company commenced a tender offer to all of its common shareholders to purchase and retire up to approximately 1,200,000 shares of its common stock at a purchase price of $1.12 per share. Upon completion of the tender offer, a total of approximately 55,000 shares of the Company's common stock, at an aggregate purchase price of approximately $62,000, were tendered to and accepted for purchase by the Company, all of which were retired. On September 25, 2007 the Company
Page 10
utilized the unused tender offer funds to purchase and retire approximately 1,100,000 shares of its common stock from the Fleming Funds at a price of $1.12 per share, for a total consideration of approximately $1,200,000.
As a consequence of the shares purchased by the Company in the tender offer, and the shares purchased by the Company from the Fleming Funds, the Company retired an aggregate of approximately 6,900,000 shares of its common stock and increased its long-term debt by approximately $5,000,000. The retirement of those shares represents more than a 26% reduction in the number of outstanding shares of the Company's common stock when compared to the total outstanding shares prior to the tender offer and the purchases from the Fleming Funds.
The sale on June 28, 2007, by the Fleming Funds to certain members of the Company's management of approximately 9,200,000 shares at a purchase price of $0.65 per share required the Company to incur a non-cash, non-recurring compensation expense and a corresponding increase to additional paid-in capital of approximately $4,338,000, both of which were recognized in the quarter ended June 30, 2007,which represents the difference between the market value of the Company's common stock on June 28, 2007 and the purchase price of the common stock. The Company's net worth was unaffected by the $4,338,000 non-cash, non-recurring charge.
Note 4 - Long-Term debt
On April 17, 2008, Hudson amended its credit facility with Keltic Financial Partners, LLP ("Keltic") and secured participation from Bridge Healthcare Financial, LLC ("Bridge") to provide for borrowings up to $15,000,000. The facility consists of a revolving line of credit and term loans, which expires on June 20, 2011. Advances under the revolving line of credit may not exceed, except as permitted in the agreement governing the credit facility, $9,000,000 and are limited to (i) 85% of eligible trade accounts receivable and (ii) 55% of eligible inventory. Advances available to Hudson under the A and B term loans may not exceed $2,500,000 and $4,500,000, respectively. At June 30, 2008, the facility bore interest at 6.5%. Substantially all of Hudson's assets are pledged as collateral for its obligations to Keltic and Bridge under the credit facility. In addition, among other things, the agreement restricts Hudson's ability to declare or pay any cash dividends on its capital stock. As of June 30, 2008, Hudson had in the aggregate $6,413,000 of borrowings outstanding and $2,587,000 available for borrowing under the revolving line of credit. In addition, the Company had $6,000,000 of borrowings outstanding under the A and B term loans with Keltic and Bridge.
In connection with the amendment to the credit facility, the Company issued 66,667 five-year common stock purchase warrants to Keltic exercisable at $1.88 per share, and issued 33,333 five-year common stock purchase warrants to Bridge exercisable at $1.88 per share. The Company utilizes the Black- Scholes pricing model to compute the fair value of the 100,000 stock purchase warrants. The $73,704, representing fair value of the warrants, is being amortized over the life of the credit facility and as of June 30, 2008 there was $67,562 unamortized debt cost, which is included in other assets on the balance sheet.
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations
Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995
Certain statements contained in this section and elsewhere in this Form 10-Q constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changes in the demand and price for refrigerants (including unfavorable market conditions adversely affecting the demand for, and the price of refrigerants), the Company's ability to source CFC and non-CFC based refrigerants, regulatory and economic factors, seasonality, competition, litigation, the nature of supplier or customer arrangements that become available to the Company in the future, adverse weather conditions, possible technological obsolescence of existing products and services, possible reduction in the carrying value of long-lived assets, estimates of the useful life of its assets, potential environmental liability, customer concentration, the ability to obtain financing, and other risks detailed in this report and in the Company's other periodic reports filed with the Securities and Exchange Commission ("SEC"). The words "believe", "expect", "anticipate", "may", "plan", "should" and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.
Critical Accounting Policies
The Company's discussion and analysis of its financial condition and results of operations are based upon its consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. Several of the Company's accounting policies involve significant judgments, uncertainties and estimations. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of
Page 11
which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. To the extent that actual results differ from management's judgments and estimates, there could be a material adverse effect on the Company. On a continuous basis, the Company evaluates its estimates, including, but not limited to, those estimates related to its allowance for doubtful accounts, inventory reserves, valuation allowance for the deferred tax assets relating to its NOL's and commitments and contingencies. With respect to accounts receivable, the Company estimates the necessary allowance for doubtful accounts based on both historical and anticipated trends of payment history and the ability of the customer to fulfill its obligations. For inventory, the Company evaluates both current and anticipated sales prices of its products to determine if a write down of inventory to net realizable value is necessary. In determining the Company's valuation allowance for its deferred tax assets, the Company assesses its ability to generate taxable income in the future. The Company utilizes both internal and external sources to evaluate potential current and future liabilities for various commitments and contingencies. In the event that the assumptions or conditions change in the future, the estimates could differ from the original estimates.
Overview
The Company has created and developed a service offering known as RefrigerantSide® Services. RefrigerantSide® Services are sold to contractors and end-users whose refrigeration systems are used in commercial air conditioning and industrial processing. These services are offered in addition to refrigerant sales and the Company's traditional refrigerant management services, which consist primarily of reclamation of refrigerants. The Company has created a network of service depots that provide a full range of the Company's RefrigerantSide® Services to facilitate the growth and development of its service offerings.
The Company focuses its sales and marketing efforts for its RefrigerantSide® Services on customers who the Company believes most readily appreciate and understand the value that is provided by its RefrigerantSide® Services offering. In pursuing its sales and marketing strategy, the Company offers its RefrigerantSide® Services to customers in the following industries; petrochemical, pharmaceutical, industrial power, manufacturing, commercial facility and property management and maritime. Moreover, to maintain its current ability to quickly respond to customer service requests throughout the United States, the Company seeks to pursue the creation of strategic alliances with companies that service larger customers in targeted industries, which, when consummated, would enable the Company to (i) co-locate its equipment with these strategic partners and (ii) utilize these partners' sales and marketing resources to offer their customers the Company's RefrigerantSide® Services. In addition, the Company has expanded its service offering outside of the United States through a strategic alliance with the Linde Group. The Company may incur additional expenses as it develops its RefrigerantSide® Services offering.
Sales of refrigerants continue to represent a significant portion of the Company revenues. Certain of the Company's refrigerant sales are CFC based refrigerants, which are no longer manufactured. The demand for CFC based refrigerants has and will continue to decrease as equipment that utilizes non-CFC based refrigerants displaces those units that utilize CFC based refrigerants. The Company has increased its refrigerant sales from non-CFC based refrigerants, including HCFC refrigerants, which are the most widely used refrigerants. The Act limits the production of HCFC refrigerants, which production was further limited in January 2004. Federal regulations enacted in January 2004 also imposed limitations on the importation of certain HCFC refrigerants. Under the Act, production of certain HCFC refrigerants are scheduled to be phased out by the year 2020, and production of all HCFC refrigerants is scheduled to be phased out by the year 2030. To the extent that the Company is unable to source CFC based or non-CFC based refrigerants on commercially reasonable terms or at all, or the demand for CFC based or non-CFC based refrigerants decreases, the Company's financial condition and results of operations could be materially adversely affected.
Results of Operations
Three month period ended June 30, 2008 as compared to the three month period ended June 30, 2007
Revenues for the three month period ended June 30, 2008 were $13,089,000 an increase of $1,782,000 or 16% from the $11,307,000 reported during the comparable 2007 period. The increase in revenues was primarily attributable to an increase in refrigerant revenues of $1,597,000 and an increase in RefrigerantSide® Services revenues of $185,000. The increase in refrigerant revenues is primarily related to an increase in the sales price of certain refrigerants sold. The increase in RefrigerantSide® Services was primarily attributable to an increase in the number of jobs completed when compared to the same period of 2007.
Cost of sales for the three month period ended June 30, 2008 was $7,945,000, a decrease of $413,000 or 5% from the $8,358,000 reported during the comparable 2007 period. The decrease in cost of sales was primarily due to a reduction in pounds sold partially offset by an increase in the cost of the pounds sold. As a percentage of sales, cost of sales was 61% of revenues for 2008, a decrease from the 74% reported for the comparable 2007 period. The decrease in cost of sales as a percentage of revenues was primarily attributable to an increase in the sales price of certain refrigerants sold when compared to the same period of 2007.
Page 12
Operating expenses for the three month period ended June 30, 2008 were $1,339,000 a decrease of $4,315,000 from the $5,654,000 reported during the comparable 2007 period. The decrease in operating expenses was primarily related to a reduction in compensation expense attributed to the non-cash, non-recurring charge of $4,338,000, in connection with the Transactions that occurred during the 2007 period.
Other income (expense) for the three month period ended June 30, 2008 was ($314,000), compared to the ($164,000) reported during the comparable 2007 period. Other income (expense) includes interest expense of $315,000 and $167,000 for the comparable 2008 and 2007 periods, respectively. The increase in interest expense is primarily attributed to an increase in outstanding indebtedness.
Income tax expense (benefit) for the three month period ended June 30, 2008 and 2007 were $492,000 and ($1,254,000) respectively. For 2008 the income tax of $492,000 was for federal and state income tax. The tax benefits associated with the Company's NOL's are recognized to the extent that the Company is expected to recognize taxable income. The Company's NOL's are subject to annual limitations and the Company expects to continue to incur certain state and federal alternative minimum taxes for the foreseeable future.
Net income for the three month period ended June 30, 2008 was $2,999,000 an increase of $4,614,000 from the ($1,615,000) net loss reported during the comparable 2007 period. The increase in net income in the 2008 period was primarily due to an increase in gross profit from an increase in refrigerant revenues and the absence of the $4,338,000 of compensation expense recorded in the 2007 period.
Six month period ended June 30, 2008 as compared to the six month period ended June 30, 2007
Revenues for the six month period ended June 30, 2008 were $24,455,000 an increase of $5,031,000 or 26% from the $19,424,000 reported during the comparable 2007 period. The increase in revenues was primarily attributable to an increase in refrigerant revenues of $4,934,000 and an increase in RefrigerantSide® Services revenues of $97,000. The increase in refrigerant revenues is primarily related to an increase in the sales price of certain refrigerants sold, which was partially offset by a reduction in the number of pounds of refrigerant sold in the 2008 period. During the first six months of 2007 the Company completed refrigerant sales to a large customer at a lower margin than those made by the Company during the 2008 period. The Company subsequently chose to discontinue refrigerant sales to this customer and has substantially replaced this volume with various smaller transactions at higher margins. The increase in RefrigerantSide® Services was primarily attributable to an increase in the numbers of jobs completed when compared to the same period of 2007.
Cost of sales for the six month period ended June 30, 2008 was $15,715,000, an increase of $798,000 or 5% from the $14,917,000 reported during the comparable 2007 period. The increase in cost of sales was primarily due to an increase in cost of certain refrigerants sold. As a percentage of sales, cost of sales was 64% of revenues for 2008, a decrease from the 77% reported for the comparable 2007 period. The decrease in cost of sales as a percentage of revenues was primarily attributable to an increase in the sales price of certain refrigerants sold when compared to the same period of 2007.
Operating expenses for the six month period ended June 30, 2008 were $2,879,000 a decrease of $3,920,000 from the $6,799,000 reported during the comparable 2007 period. The decrease in operating expenses was primarily related to a reduction in compensation expense attributed to the non-cash, non-recurring charge of $4,338,000 in connection with the Transactions that occurred during the 2007 period partially offset by increased selling expenses and professional fees.
Other income (expense) for the six month period ended June 30, 2008 was ($567,000), compared to the ($294,000) reported during the comparable 2007 period. Other income (expense) includes interest expense of $569,000 and $306,000 for the comparable 2008 and 2007 periods, respectively. The increase in interest expense is primarily attributed to an increase in outstanding indebtedness.
Income tax expense (benefit) for the six month period ended June 30, 2008 and 2007 were $544,000 and ($1,254,000) respectively. For 2008 the income tax of $544,000 was for federal and state income. The tax benefits associated with the Company's NOL's are recognized to the extent that the Company is expected to recognize taxable income. The Company's NOL's are subject to annual limitations and the Company expects to continue to incur certain state and federal alternative minimum taxes for the foreseeable future.
Net income for the six month period ended June 30, 2008 was $4,750,000 an increase of $6,082,000 from the ($1,332,000) net loss reported during the comparable 2007 period. The increase in net income in the 2008 period was primarily due to an increase in gross profit from an increase in refrigerant revenues and the absence of the $4,338,000 of compensation expense recorded in the 2007 period.
Page 13
Liquidity and Capital Resources
At June 30, 2008, the Company had working capital, which represents current assets less current liabilities, of $12,154,000 an increase of $4,611,000 from the working capital of $7,543,000 at December 31, 2007. The increase in working capital is primarily attributable to net income during the period.
Inventory and trade receivables are principal components of current assets. At June 30, 2008, the Company had inventories of $15,217,000, an increase of $2,615,000 or 21% from the $12,602,000 at December 31, 2007. The increase in the inventory balance is due to the timing and availability of inventory purchases and the sale of refrigerants. The Company's ability to sell and replace its inventory on a timely basis and the prices at which it can be sold are subject, among other things, to current market conditions and the nature of supplier or customer arrangements and the Company's ability to source CFC based refrigerants, which are no longer being manufactured or non-CFC based refrigerants. At June 30, 2008, the Company had trade receivables, net of allowance for doubtful accounts of $7,435,000 an increase of $5,689,000 from the $1,746,000 at December 31, 2007. The Company's trade receivables are concentrated with various wholesalers, brokers, contractors and end-users within the refrigeration industry that are primarily located in the continental United States.
The Company has historically financed its working capital requirements through cash flows from operations, the issuance of debt and equity securities, and bank borrowings.
Net cash used by operating activities for the six month period ended June 30, 2008, was $3,534,000 compared with net cash provided by operating activities of $1,338,000 for the comparable 2007 period. Net cash used by operating activities for the 2008 period was primarily attributable to increases in accounts receivable and inventory of $5,749,000 and $2,615,00, respectively, partially offset by net income.
Net cash used by investing activities for the six month period ended June 30, 2008, was $466,000 compared with net cash used by investing activities of $266,000 for the prior comparable 2007 period. The net cash used by investing activities for the 2008 period was primarily related to investment in general purpose equipment and purchase of land in Champaign, IL.
Net cash provided by financing activities for the six month period ended June 30, 2008, was $4,541,000 compared with net cash used by financing activities of $201,000 for the comparable 2007 period. The net cash provided by financing activities for the 2008 period was due to borrowings under the Company's revolving line of credit and proceeds of issuance of common stock offset by repayments of long term debt.
At June 30, 2008, the Company had cash and cash equivalents of $824,000. The Company continues to assess its capital expenditure needs. The Company may, to the extent necessary, continue to utilize its cash balances to purchase equipment primarily for its operations. The Company estimates that the total capital expenditures for 2008 will be approximately $800,000.
The following is a summary of the Company's significant contractual cash obligations for the periods indicated that existed as of June 30, 2008.
|
12 Month Period ended June 30, |
||||||
|
|
|
|
|
2013 |
|
|
|
2009 |
2010 |
2011 |
2012 |
And after |
Total |
|
Long and short term debt and capital lease |
$8,388 |
$1,965 |
$5,133 |
$134 |
$877 |
$16,497 |
|
obligations (1) & (2) |
|||||||
Operating leases |
383 |
324 |
235 |
84 |
41 |
1,067 |
|
Total contractual cash obligations |
$8,771 |
$2,289 |
$5,368 |
$218 |
$918 |
$17,564 |
|
|
===== |
===== |
===== |
==== |
==== |
===== |
____________
(1) The contractual cash obligations included in the table includes both principal and estimated interest payments. The estimated interest payments on revolving debt are based primarily on the interest rates in effect and the outstanding revolving debt obligation as of June 30, 2008. |
(2) Long and short term debt and capital lease obligations include payment of obligations of outstanding principal amounts of debt as of June 30, 2008 and estimated future interest payments on the outstanding principal amounts under the Company's credit facility with Keltic and Bridge, which expires on June 20, 2011. |
|
On April 17, 2008, Hudson amended its credit facility with Keltic and secured participation from Bridge to provide for borrowings up to $15,000,000. The facility consists of a revolving line of credit and term loans, which expires on June 20, 2011. Advances under the revolving line of credit may not exceed, except as permitted in the agreement governing the credit facility, $9,000,000
Page 14
and are limited to (i) 85% of eligible trade accounts receivable and (ii) 55% of eligible inventory. Advances available to Hudson under the A and B term loans may not exceed $2,500,000 and $4,500,000, respectively. At June 30, 2008, the facility bore interest at 6.5%. Substantially all of Hudson's assets are pledged as collateral for its obligations to Keltic and Bridge under the credit facility. In addition, among other things, the agreement restricts Hudson's ability to declare or pay any cash dividends on its capital stock. As of June 30, 2008, Hudson had in the aggregate $6,413,000 of borrowings outstanding and $2,587,000 available for borrowing under the revolving line of credit. In addition, the Company had $6,000,000 of borrowings outstanding under the A and B term loans with Keltic and Bridge.
In connection with the amendment to the credit facility, the Company issued 66,667 five-year common stock purchase warrants to Keltic exercisable at $1.88 per share, and issued 33,333 five-year common stock purchase warrants to Bridge exercisable at $1.88 per share.
On June 28, 2007, the Company purchased and retired approximately 5,700,000 shares of its common stock from the Fleming Funds at a purchase price of $0.65 per share, for total consideration of approximately $3,700,000. Additionally, certain members of the Company's management, in separate private transactions, purchased approximately 9,200,000 shares of the Company's common stock from the Fleming Funds at a purchase price of $0.65 per share, for a total consideration of approximately $6,000,000. The shares purchased by management are unregistered shares and management did not receive registration rights in connection with their purchase of their shares.
On June 29, 2007 the Company commenced a tender offer to all of its common shareholders to purchase and retire up to approximately 1,200,000 shares of its common stock at a purchase price of $1.12 per share. Upon completion of the tender offer, a total of approximately 55,000 shares of the Company's common stock, at an aggregate purchase price of approximately $62,000, were tendered to and accepted for purchase by the Company, all of which were retired. On September 25, 2007 the Company utilized the unused tender offer funds to purchase and retire approximately 1,100,000 shares of its common stock from the Fleming Funds at a price of $1.12 per share, for a total consideration of approximately $1,200,000.
As a consequence of the shares purchased by the Company in the tender offer, and the shares purchased by the Company from the Fleming Funds, in 2007 the Company retired an aggregate of approximately 6,900,000 shares of its common stock and has increased its long-term debt by approximately $5,000,000. The retirement of those shares represents more than a 26% reduction in the number of outstanding shares of the Company when compared to the total outstanding shares prior to the tender offer and the purchases from the Fleming Funds.
In May 2005, the Company purchased its Champaign, Illinois facility for a total purchase price of $999,999. The Company financed the purchase with a 15 year amortizing loan in the amount of $945,000 with a balloon payment due on September 1, 2012. The note bears interest at 7% for the first five years and then adjusts annually based on prime plus 2%.
The Company believes that it will be able to satisfy its working capital requirements for the next twelve months from anticipated cash flows from operations and available funds under its existing credit facility. Any unanticipated expenses, including, but not limited to, an increase in the cost of refrigerants purchased by the Company, an increase in operating expenses or failure to achieve expected revenues from the Company's RefrigerantSide® Services and/or refrigerant sales or additional expansion or acquisition costs that may arise in the future would adversely affect the Company's future capital needs. There can be no assurances that the Company's proposed or future plans will be successful, and as such, the Company may require additional capital sooner than anticipated, which capital may not be available.
Inflation
Inflation has not historically had a material impact on the Company's operations.
Reliance on Suppliers and Customers
The Company's financial performance and its ability to sell refrigerants is in part dependent on its ability to obtain sufficient quantities of virgin, non-CFC based refrigerants, and of reclaimable, primarily CFC based, refrigerants from manufacturers, wholesalers, distributors, bulk gas brokers, and from other sources within the air conditioning, refrigeration and automotive aftermarket industries, and on corresponding demand for refrigerants. The Company's refrigerant sales include CFC based refrigerants, which are no longer manufactured. Additionally, the Company's refrigerant sales include non-CFC based refrigerants, including HCFC refrigerants, which are the most widely used refrigerants. Effective January 1, 1996, the Act limits the production of HCFC refrigerants, which production was further limited in January 2004. Federal regulations enacted in January 2004 also imposed limitations on the importation of certain HCFC refrigerants. Under the Act, production of certain HCFC refrigerants is scheduled to be phased out by the year 2020 and production of all HCFC refrigerants is scheduled to be phased out by the year 2030. The limitations imposed by and under the Act, may limit supplies of virgin refrigerants for the foreseeable future or cause a significant increase in the price of virgin HCFC refrigerants. To the extent the Company is unable to source sufficient quantities of
Page 15
virgin or reclaimable refrigerants in the future, or resell refrigerants at a profit, the Company's financial condition and results of operations would be materially adversely affected.
For the six month period ended June 30, 2008 one customer accounted for approximately 11% of the Company's revenues. For the six month period ended June 30, 2007 one customer accounted for approximately 16% of the Company's revenues.
The loss of a principal customer or a decline in the economic prospects of and/or a reduction in purchases of the Company's products or services by any such customer could have a material adverse effect on the Company's financial position and results of operations.
Seasonality and Fluctuations in Operating Results
The Company's operating results vary from period to period as a result of weather conditions, requirements of potential customers, non-recurring refrigerant and service sales, availability and price of refrigerant products (virgin or reclaimable), changes in reclamation technology and regulations, timing in introduction and/or retrofit or replacement of CFC and non CFC based refrigeration equipment, the rate of expansion of the Company's operations, and by other factors. The Company's business is seasonal in nature with peak sales of refrigerants occurring in the first half of each year. During past years, the seasonal decrease in sales of refrigerants has resulted in losses particularly in the fourth quarter of the year. Delays or inability in securing adequate supplies of refrigerants at peak demand periods, lack of refrigerant demand, increased expenses, declining refrigerant prices and a loss of a principal customer could result in significant losses. There can be no assurance that the foregoing factors will not occur and result in a material adverse effect on the Company's financial position and significant losses. The Company believes that there is a similar seasonal element to RefrigerantSide® Service revenues as refrigerant sales. The Company is continuing to assess its RefrigerantSide® Service revenues seasonal trend.
Recent Accounting Pronouncements
In September 2006, the FASB issued FASB statement No. 157 ("SFAS No. 157,") "Fair Value Measurements," which establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. SFAS No. 157 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. SFAS No. 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The FASB agreed to defer the effective date of Statement 157 for one year for non-financial assets and non-financial liabilities that are recognized or disclosed at fair value in the financial statements on a nonrecurring basis. There is no deferral for financial assets and financial liabilities, nor for the rare non-financial assets and non-financial liabilities that are remeasured at fair value at least annually. The adoption of SFAS No. 157 did not have a material impact on the Company's results of operations or its financial position.
Item 3 - Quantitative and Qualitative Disclosures about Market Risk
Not Applicable
Item 4T - Controls and Procedures
Disclosure Controls and Procedures
The Company, under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company's disclosure controls and procedures, as defined in Rule 13a-15(e) of the Securities Exchange Act or 1934, as amended ("Exchange Act"), as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer have concluded that the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to the Company's management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Because of the inherent limitations in all control systems, any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Furthermore, the Company's controls and procedures can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control, and misstatements due to error or fraud may occur and not be detected on a timely basis.
Page 16
Changes in Internal Control Over Financial Reporting
There were no changes in the Company's internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) in the quarter ended June 30, 2008 that materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.
Page 17
PART II - OTHER INFORMATION
Item 1 - Legal Proceedings
For information regarding pending legal matters, refer to the Legal Proceedings Section in Part I, Item 3 of the Company's Form 10-KSB for the year ended December 31, 2007.
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds
In connection with the amendment to the Company's credit facility with Keltic and Bridge in April 2008, the Company issued 66,667 five-year common stock purchase warrants to Keltic exercisable at $1.88 per share, and issued 33,333 five-year common stock purchase warrants to Bridge exercisable at $1.88 per share. In addition, during the quarter ended June 30, 2008 the Company issued an aggregate of 34,123 shares of its restricted common stock to a total of six individual investors upon their exercise of warrants previously issued to them by the Company. The securities referred to above were issued by the Company in private transactions without registration under the Securities Act of 1933, as amended (the "Act") in reliance upon the exemption from registration provided under section 4 (2) of the Act. Each of Keltic and Bridge and the exercising warrant holders acknowledged, among other things, that they were acquiring the respective securities acquired by them for investment and the certificates for the securities issued contained a legend regarding restrictions on transfer under the Act.
Item 6 - Exhibits
The following exhibits are attached to this report: |
|
10.1 Second Amendment to Amended and Restated Loan Agreement between Hudson Technologies Company, Keltic Financial Partners, L.P and Bridge Healthcare Finance, LLC, dated April 17, 2008 (1) |
10.2 Second Amended, Restated and Bifurcated Revolving Note, dated April 17, 2008, in the amount of $10,000,000 (1) |
10.3 Second Amended, Restated and Bifurcated Revolving Note, dated April 17, 2008, in the amount of $5,000,000 (1) |
10.4 Second Amended, Restated and Bifurcated Term Note A, dated April 17, 2008 in the amount of $1,666,666.67 (1) |
10.5 Second Amended, Restated and Bifurcated Term Note A, dated April 17, 2008 in the amount of $833,333.33 (1) |
10.6 Amended, Restated and Bifurcated Term Note B, dated April 17, 2008, in the amount of $3,000,000 (1) |
10.7 Amended, Restated and Bifurcated Term Note B, dated April 17, 2008, in the amount of $1,500,000 (1) |
10.8 Warrant to Purchase Common Stock, dated April 17, 2008, for 66,667 shares of Common Stock issued to Keltic Financial Partners, L.P. (1) |
10.9 Warrant to Purchase Common Stock, dated April 17, 2008, for 33,333 shares of Common Stock issued to Bridge Healthcare Finance, LLC (1) |
31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
_________________
(1) Incorporated by reference to the comparable exhibit filed with the Company's current report on Form 8-K for the event dated April 17, 2008 filed with the SEC on April 22, 2008.
Page 18
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this Report to be signed in its behalf by the undersigned, thereunto duly authorized.
HUDSON TECHNOLOGIES, INC.
By: |
/s/ Kevin J. Zugibe |
August 12, 2008 |
Kevin J. Zugibe |
Date |
|
Chairman and |
||
Chief Executive Officer |
By: |
/s/ James R. Buscemi |
August 12, 2008 |
James R. Buscemi |
Date |
|
Chief Financial Officer |
Exhibit Index
Number
10.1 |
Second Amendment to Amended and Restated Loan Agreement between Hudson Technologies Company, Keltic Financial Partners L.P. and Bridge Healthcare Finance, LLC, dated April 17, 2008 (1) |
10.2 |
Second Amended, Restated and Bifurcated Revolving Note, dated April 17, 2008 in the amount of $10,000,000 (1) |
10.3 |
Second Amended, Restated and Bifurcated Revolving Note, dated April 17, 2008, in the amount of $5,000,000 (1) |
10.4 |
Second Amended, Restated and Bifurcated Term Note A, dated April 17, 2008 in the amount of $1,666,666.67 (1) |
10.5 |
Second Amended, Restated and Bifurcated Term Note A, dated April 17, 2008 in the amount of $833,333.33 (1) |
10.6 |
Amended, Restated and Bifurcated Term Note B, dated April 17, 2008, in the amount of $3,000,000 (1) |
10.7 |
Amended, Restated and Bifurcated Term Note B, dated April 17, 2008, in the amount of $1,500,000 (1) |
10.8 |
Warrant to Purchase Common Stock, dated April 17, 2008, for 66,667 shares of Common Stock issued to Keltic Financial Partners, L.P. (1) |
10.9 |
Warrant to Purchase Common Stock, dated April 17, 2008, for 33,333 shares of Common Stock issued to Bridge Healthcare Finance, LLC (1) |
31.1 |
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
31.2 |
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
32.1 |
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 |
32.2 |
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
_________________
(1) Incorporated by reference to the comparable exhibit filed with the Company's current report on Form 8-K for the event dated April 17, 2008 filed with the SEC on April 22, 2008.